ABK Biomedical partners with the CNIC to enhance patient care

ABK Biomedical, which is developing a transformative Eye90 microspheres® technology, with the potential to provide in-procedure prognostic dosimetry for cutting-edge treatment of liver tumours – has partnered with the Canadian Nuclear Isotope Council.

The CNIC is an independent body made up of representatives from the Canadian health sector, nuclear industry and leading research groups to help deliver innovative cancer treatments to patients. ABK Biomedical is the latest company to get on board as a partner.

James Scongack, Chair of the CNIC, welcomed ABK Biomedical as the latest Council advocate for the production of medical isotopes and finding new ways to treat cancer.

In September, the CNIC released a report highlighting the need for a Pan-Canadian strategy on isotopes led by the federal government to ensure a domestic and international supply of medical isotopes. The report makes it clear that Canada must invest in its isotope infrastructure as these investments would show a commitment to our role as a leader in nuclear medicine, and dramatically bolster the country’s capacity to innovate while delivering substantial economic and societal benefits to both Canadians and patients around the globe.

This year, the CNIC is focused on bridging these public and private coalitions into demonstrable results for Canadians, searching for new life-saving cancer treatments. The CNIC will continue to promote public awareness about the use and benefits of medical/industrial isotopes and radiation technologies, and work with government stakeholders to ensure that the public policy landscape promotes innovation and supports the increased proliferation of medical and industrial isotope uses.